Angiotensin II type 1 receptor blockade in the prevention of in-stent restenosis: systemic versus local delivery.

摘要

We have read with great interest the article by Groenewegen et al. entitled 'Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation' [1]. In that article, the authors evaluated the effect of supraphysiologic levels of angiotensin II and selective angiotensin II type 1 receptor (ATI-receptor) blockade on neointimal formation and systemic endothelial function after stent implantation in the rat abdominal aorta. They found that candesartan cilexetil treatment did not result in reduction of neointimal area and did not reduce neointimal thickness compared to the control group. Also candesartan had no effect on endothelial function [1]. They concluded that supraphysiologic levels of angiotensin II aggravate neointimal formation in the stented rat abdominal aorta, and in parallel decreases endothelial function. ATI-receptor blockade does not reduce neointimal formation in rats without supraphysiologic angiotensin II levels.